Ozempic: the gold standard for weight normalisation or a “lifeboat”
Open Access
- 31 March 2026
- journal article
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 160 (1)
Abstract
Obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome remain prevalent global health challenges requiring comprehensive management strategies. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has emerged as a significant pharmacological intervention. The study aims to analyze current scientific data to critically assess the clinical efficacy and safety of semaglutide (Ozempic) in treating T2DM and obesity, determining its position in modern therapeutic protocols. A descriptive review of the literature was conducted, analyzing key phase III clinical trials, including the SUSTAIN, PIONEER, STEP, and SELECT programmes. The review focuses on pharmacokinetic properties, glycaemic control, weight loss outcomes, and cardiovascular safety profiles of both subcutaneous and oral semaglutide formulations. Clinical trials demonstrate that semaglutide significantly reduces glycated haemoglobin (HbA1c) by -1.0% to -1.8% and induces substantial weight loss(averaging ~15%), surpassing earlier GLP-1RAs. The drug exhibits pleiotropic effects, including improved endothelial function and reduced inflammation, contributing to cardiovascular protection, with a relative reduction of major adverse cardiovascular events (MACE) by ~20%. However, rapid weight regains upon discontinuation and potential adverse effects such as gastrointestinal disturbances remain significant concerns. Semaglutide represents a highly effective pharmacological option for managing metabolic disorders, offering benefits beyond glycaemic control. While it sets a high standard for efficacy, issues regarding cost, accessibility, and the necessity for long-term adherence categorize it as a specialized resource requiring strategic implementation rather than a universally accessible cure.Keywords
This publication has 8 references indexed in Scilit:
- Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trialsEuropean Heart Journal, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEFJACC: Basic To Translational Science, 2023
- Semaglutide for the treatment of overweight and obesity: A reviewDiabetes, Obesity and Metabolism, 2022
- Corrigendum: Safety of SemaglutideFrontiers in Endocrinology, 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016